PMID- 31124299
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 21
IP  - 8
DP  - 2019 Aug
TI  - Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with 
      high HbA1c or those with inadequate glycaemic control on two oral 
      antihyperglycaemic drugs in the LixiLan-O randomized trial.
PG  - 1967-1972
LID - 10.1111/dom.13791 [doi]
AB  - In this post hoc analysis of the randomized controlled LixiLan-O trial in 
      insulin-naive patients with type 2 diabetes mellitus (T2DM) not controlled with 
      metformin, with or without a second oral antihyperglycaemic drug (OAD), the 
      efficacy and safety of the fixed-ratio combination, iGlarLixi (insulin glargine 
      100 U [iGlar] and lixisenatide [Lixi]), compared to its individual components was 
      assessed in two patient subgroups: group 1) baseline HbA1c >/=9% (n = 134); group 
      2) inadequate control (HbA1c >/=7.0% and </=9.0%) despite administration of two OADs 
      at screening (n = 725). Treatment with iGlarLixi resulted in significantly 
      greater reduction in least squares mean HbA1c compared to treatment with iGlar or 
      Lixi alone in both subgroups (group 1: 2.9%, 2.5%, 1.7% and group 2: 1.5%, 1.2%, 
      0.7%, respectively). Target HbA1c less than 7% was achieved in more than 70% of 
      patients using iGlarLixi in both subgroups, while mitigating the weight gain 
      observed with use of iGlar alone. Rates of hypoglycaemic events were low overall. 
      These results suggest that treatment with iGlarLixi achieves superior glycaemic 
      control compared to treatment with iGlar or Lixi alone in T2DM patients with 
      HbA1c >/=9% or in those inadequately controlled with two OADs.
CI  - (c) 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Davies, Melanie J
AU  - Davies MJ
AUID- ORCID: 0000-0002-9987-9371
AD  - Department of Health Services, Diabetes Research Centre, University of Leicester, 
      Leicester General Hospital and University Hospitals of Leicester NHS Trust, 
      Leicester, UK.
FAU - Russell-Jones, David
AU  - Russell-Jones D
AUID- ORCID: 0000-0002-9490-2480
AD  - Department of Diabetes and Endocrinology, University of Surrey, Guildford, UK.
FAU - Barber, Thomas M
AU  - Barber TM
AUID- ORCID: 0000-0003-0689-9195
AD  - Translational Medicine, Warwick Medical School, University of Warwick, Coventry, 
      UK.
FAU - Lavalle-Gonzalez, Fernando J
AU  - Lavalle-Gonzalez FJ
AD  - Department of Endocrinology, Hospital Universitario "Dr. Jose Eleuterio 
      Gonzalez", Monterrey, Mexico.
FAU - Galstyan, Gagik R
AU  - Galstyan GR
AD  - Diabetic Foot Department, Endocrinology Research Center, Moscow, Russia.
FAU - Zhu, Dalong
AU  - Zhu D
AD  - Department of Endocrinology, Affiliated Drum Tower Hospital, Nanjing University 
      Medical School, Nanjing, China.
FAU - Baxter, Mike
AU  - Baxter M
AD  - Sanofi, Guildford, UK.
FAU - Dessapt-Baradez, Cecile
AU  - Dessapt-Baradez C
AD  - Sanofi, Guildford, UK.
FAU - McCrimmon, Rory J
AU  - McCrimmon RJ
AD  - Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, 
      UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT02058147
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190618
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 74O62BB01U (lixisenatide)
SB  - IM
MH  - Adult
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/*drug effects
MH  - Humans
MH  - Hypoglycemia/chemically induced/epidemiology
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin Glargine/*administration & dosage
MH  - Least-Squares Analysis
MH  - Male
MH  - Middle Aged
MH  - Peptides/*administration & dosage
MH  - Treatment Outcome
MH  - Weight Gain/drug effects
PMC - PMC6772132
OTO - NOTNLM
OT  - glycaemic control
OT  - iGlarLixi
OT  - insulin glargine 100 U
OT  - lixisenatide
OT  - type 2 diabetes mellitus
COIS- M. J. D. serves on Advisory Panels for AstraZeneca, Boehringer Ingelheim, Eli 
      Lilly, Janssen, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis and Servier; 
      serves as a consultant to AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, 
      Merck Sharp & Dohme, Novo Nordisk and Sanofi-Aventis; has received research 
      support (grants in support of investigator trials) from Boehringer Ingelheim, Eli 
      Lilly, Janssen, Novo Nordisk and Sanofi-Aventis; and is a member of speakers 
      bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & 
      Dohme, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk, Sanofi-Aventis and 
      Takeda. D. R-J. serves on Advisory Panels for, is a Board member of and 
      consultant to, and has received research support from AstraZeneca, Eli Lilly, 
      Novo Nordisk and Sanofi; and is a member of speakers bureaus for AstraZeneca, 
      Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Takeda. T. M. B. serves 
      on Advisory Panels for AstraZeneca, Boehringer Ingelheim, Napp Pharmaceuticals, 
      Novo Nordisk and Sanofi; and has received research support from AstraZeneca, 
      Bayer and Shire. F. J. L-G. serves on Advisory Panels for AstraZeneca, Boehringer 
      Ingelheim, Eli Lilly, Janssen, Novo Nordisk and Sanofi; is a Board member of 
      AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk and Sanofi; and is a 
      member of speakers bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, 
      Janssen, Merck Sharp & Dohme, Novo Nordisk and Sanofi. G. R. G. serves on 
      Advisory Panels for AbbVie, AstraZeneca, Merck Sharp & Dohme, Novo Nordisk, 
      Pfizer and Sanofi; and is a member of speakers bureaus for Amgen, AstraZeneca, 
      Berlin Chemie, Boehringer Ingelheim, Eli Lilly, LifeScan, Merck Sharp & Dohme, 
      Novartis, Novo Nordisk, Sanofi, Servier and Takeda. D. Z. has nothing to 
      disclose. M. B. is an employee of and stock/shareholder in Sanofi; is Honorary 
      Associate Professor at the University of Swansea; and is Non-Executive Director 
      of Ashford and St Peter's Hospital NHS Foundation Trust. C. D-B. is an employee 
      of and stock/shareholder in Sanofi. R. J. M. serves on Advisory Panels for Eli 
      Lilly, Novo Nordisk, Sanofi; and is a member of speakers bureaus for Eli Lilly 
      and Sanofi.
EDAT- 2019/05/28 06:00
MHDA- 2020/09/17 06:00
PMCR- 2019/10/01
CRDT- 2019/05/25 06:00
PHST- 2019/04/10 00:00 [received]
PHST- 2019/05/17 00:00 [revised]
PHST- 2019/05/20 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2019/05/25 06:00 [entrez]
PHST- 2019/10/01 00:00 [pmc-release]
AID - DOM13791 [pii]
AID - 10.1111/dom.13791 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2019 Aug;21(8):1967-1972. doi: 10.1111/dom.13791. Epub 2019 
      Jun 18.